Derek Chang – Head, Novartis Hong Kong
Novartis, one of the world’s largest biopharma companies, has secured approval and market access for two of its most advanced cell and gene treatments in Hong Kong. The firm’s territory…
Address: 43rd Floor, Gloucester Tower, The Landmark, 15 Queen’s Road Central, Hong Kong
Tel: +852 2218 9100
Web: http://www.orrick.com/Offices/Hong-Kong/Pages/default.aspx
Hong Kong is uniquely positioned at the doorsteps of the world’s fastest growing major economy of the 21st century and the lawyers on Orrick’s China Team have been there since the first days those doors were opened. In 1972, Coudert Brothers was the first foreign law firm to open an office in Hong Kong and, in November 2005, the entire 25-lawyer office of Coudert joined Orrick, opening Orrick’s first of three China-focused offices. Orrick’s offices in Beijing and Shanghai opened in 2006 when most of Coudert’s lawyers in Beijing and Shanghai also joined Orrick. In addition to being first in Hong Kong, Coudert was the first foreign law firm to establish a permanent presence in Beijing (1979), the first foreign law firm to be approved by the Ministry of Justice to establish a law office in China (Beijing, 1992; with the receipt of license no. 001) and one of the first foreign law firms to open an office in Shanghai (2001).
For more than three decades, Orrick’s Hong Kong lawyers have been guiding the world’s most prominent businesses through many of the first and most complex commercial and financial transactions involving China, including:
* The Coca-Cola Company
* McDonald’s
* S.C. Johnson & Sons, Inc.
* Carrefour
* General Motors Corporation
* NEC Corporation
* Occidental Petroleum
Beyond China, the Hong Kong team’s experience extends throughout the Asia-Pacific region on significant transactions including the “London Club” of more than 60 commercial banks in a series of jumbo loans of more than $1.5 billion of U.S. dollar- and yen-denominated sovereign debt extended to the Republic of Indonesia; Telenor Ltd. (a Norwegian telecommunications company) in acquiring shares in two Thai telecommunications companies; foreign investors in a series of acquisitions and divestitures in the electric power generating sector in the Philippines; and structuring and advising many of the first hedge funds and private equity funds organized with investors from multiple jurisdictions for investment targets throughout the Asia-Pacific region.
International Reputation
The reputation of Orrick’s Hong Kong lawyers is well recognized by recent awards from leading global publications, including:
* M&A Deal of the Year
* Real Estate and Construction Deal of the Year
* Logistics Deal of the Year
Unique Qualifications
Orrick’s Hong Kong team is strongly positioned to assist local and international clients with sophisticated transactions that cross multiple jurisdictions. Orrick’s Hong Kong office provides clients with a unique combination of lawyers who are qualified in multiple jurisdictions, fluent in multiple languages, graduates of many of the world’s most well respected legal and business universities, experienced in business operations and management, and have served in government positions.
* Multiple Jurisdictions
Orrick’s Hong Kong lawyers have more than 30 years of experience handling corporate, commercial, securities, finance, litigation and arbitration matters under the laws of the multiple jurisdictions where local lawyers are qualified – Hong Kong, Australia, the United States, England and Wales.
* Multiple Language Capabilities
In addition to being qualified to practice in multiple jurisdictions, Orrick’s Hong Kong office also provides clients with lawyers who are fluent in multiple languages, including English, Cantonese, French, Korean, Mandarin and Putonghua.
* Legal Educations and Business Backgrounds
Lawyers in Orrick’s Hong Kong office have received graduate degrees (J.D./LL.B., LL.M., M.B.A., B.A. and B.S.) from well-known universities in the United States, the United Kingdom, Australia, China and Hong Kong, including Chinese University of Hong Kong, Columbia University, Fudan University (Shanghai), Harvard Law School, London School of Economics, New York Law School, Stanford Law School, University of California (Berkeley), University of Hong Kong, University of Melbourne, University of New South Wales, University of Southern California (Los Angeles), University of International Business and Economics (Beijing) and Yale College.
Orrick’s team of lawyers also includes lawyers with diverse backgrounds, including a lawyer who began advising foreign companies on China matters in 1980 as a Beijing-based business representative and consultant, a lawyer who practiced in California and Korea before moving to Hong Kong in 1993, a lawyer who worked for the Department of Justice of the Hong Kong Government, and a lawyer who held numerous Shenzhen-based management positions. The Hong Kong office is also staffed by Chinese and foreign consultants, legal assistants, trainee solicitors and translators.
Banking and Bank Regulatory Matters, Dispute Resolution, Emerging Companies and Venture Capital, Employment Law, Finance and Project Finance, Financial Markets, Intellectual Property, Internal Investigations, Life Sciences, Media and Entertainment, Mergers and Acquisitions, Private Equity, Investment Funds and Venture Capital, Real Estate Development and Finance, Restructuring, Securities, Tax
Novartis, one of the world’s largest biopharma companies, has secured approval and market access for two of its most advanced cell and gene treatments in Hong Kong. The firm’s territory…
Generative Artificial Intelligence (AI) has grabbed a lot of media attention in recent months following the launch of chatbot ChatGPT, but the pharmaceutical industry has long been trying – and…
One of Asia’s most pre-eminent oncologists, Professor Tony Mok is perhaps best known for discovering the EGFR mutation gene and subsequently developing a targeted therapy that is more precise and…
Established in 2017 as a spin-off from Lee’s Pharmaceutical, Zhaoke Ophthalmology is aiming to be a global player in the ophthalmology field, building on its strong footprint in China and…
Serial entrepreneur Danny Yeung highlights the work of his Hong Kong-based genomics-driven firm Prenetics in prevention, early detection and targeted therapy. Having recently announced a USD 200 million joint venture…
Since first allowing pre-revenue biotechs to list in 2018, the Hong Kong stock exchange has welcomed 59 such companies and is now a leading vehicle for allowing Chinese biopharma to…
The Hong Kong Association of the Pharmaceutical Industry (HKAPI) represents the interests of the global R&D-based biopharmaceutical industry in Hong Kong and Macau. Senior Executive Director Sabrina Chan outlines the…
AstraZeneca, the largest overseas pharmaceutical company in mainland China by sales, is also the market leader in Hong Kong and Macau, a territory overseen by General Manager Shan Wu. She…
First set up in 2014, the Guangdong Medical Valley is an investment incubation platform in southern China focusing on the biomedical and medical device industries. CEO Xia Jiasheng explains how…
Fresh from the news that one of its AI-designed and discovered drug candidates has entered Phase II human clinical trials – the first time that such a project has made…
The Guangzhou production site of HKEX-listed RNA therapeutics biotech Sirnaomics is overseen by pharma industry veteran Edward Wang. Here, Wang explains his contribution to the development of good manufacturing practices…
Lawrence Wong outlines how reproductive medicine-focused Ferring Pharmaceuticals is serving the patients of Hong Kong as the city’s birth rates have plateaued, weighs in on why the establishment of a…
See our Cookie Privacy Policy Here